Leo Ehrlich interview October 2012

Many biotechnology companies find their drug candidate pigeon-holed to one particular indication, but we have found KEVETRIN to produce robust results in both solid tumors and blood tumors. We knew we had to move this to clinical trials as quickly as possible.

If Kevetrin's Phase I results were in line with laboratory data, would you request FDA to pass directly to Phase III?

[LEO] Obviously, YES!